Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma

REN Tao; et al

您当前的位置：

首页 >

文章列表页 >

Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma

更新时间：2024-01-17

- Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma
- Journal of Chongqing Medical University Issue 1, Pages: 76-78(2007)
- 作者机构：
  
  1. 重庆医科大学附属第一医院肿瘤科
  2. 重庆医科大学附属第一医院肿瘤科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：
  CLC： R735.1
- Published：2007，
扫描看全文
[1]任涛,张菊,陈晓品.放射治疗结合新辅助化疗治疗食管上段癌观察[J].重庆医科大学学报,2007(01):76-78.

REN Tao, et al. Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma. [J]. Journal of Chongqing Medical University (1):76-78(2007)
[1]任涛,张菊,陈晓品.放射治疗结合新辅助化疗治疗食管上段癌观察[J].重庆医科大学学报,2007(01):76-78. DOI：

REN Tao, et al. Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma. [J]. Journal of Chongqing Medical University (1):76-78(2007) DOI：

摘要

目的:探讨放射治疗结合新辅助化疗治疗食管上段癌的临床疗效。方法:45例食管上段癌随机分为两组

23例进入新辅助化疗+放射治疗组（化放组）

22例进入单纯放射治疗组（单放组）。新辅助化疗方案为顺铂加5-Fu

连续2个周期

化疗后2￣3周开始放射治疗。化放组在放射治疗的后四周给于口服卡莫氟化疗药物

两组放射治疗方法相同。结果:1、2、3年生存率化放组分别为73.91%、56.52%、47.83%

单放组分别为59.09%、31.82%、18.18%

生存率比较化放组优于单放组

统计分析结果χ2=4.3406（P=0.0372）;化放组的毒副反应较重

但患者皆可以耐受。结论:PF方案的新辅助化疗结合放射治疗可以提高上段食管癌的疗效。

Abstract

Objective:To evaluate the effect of radiotherapy combined with neoadjuvant chemotherapy on patients with upper esophageal carcinoma.Methods:Forty-five patients with upper esophageal carcinoma were divided into two groups randomly. There were 23 patients in neoadjuvant chemotherapy plus radiotherapy group(CR)

and 22 patients in radiotherapy group(R).The regimen of neoadjuvant chemotherapy including cisplatin and 5-fluorouracil was administered.Two to three weeks after two cycles of chemotherapy

the patients were irradiated.Carmofur in CR group was administered in the period of late-course radiotherapy for four weeks

and the methods of radiotherapy were identical in two groups.Results:The 1

3-year survival rates were 73.91%

56.52% and 47.83% for CR group and 59.09%

31.82% and 18.18% for R group

and survival rates differed significantly(χ2=4.8112、P =0.0283)in two groups;however

more serious side effects were in CR group

but they could be tolerated by patients.Conclusions:Neoadjuvant chemotherapy with PF regimen plus radiotherapy may improve the outcome of upper esophageal carcinoma.

关键词

食管肿瘤化学疗法新辅助化疗食管肿瘤放射疗法

Keywords

Esophageal neoplasmschemotherapyneoadjuvant chemotherapyEsophageal neoplasmsradiotherapy

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Prediction of chemosensitivity to combination neoadjuvant chemotherapy with carboplatin and 5-Fu for the patients with oral squamous cell carcinoma

Relationship between expression of p53、cerbB-2 and the effect of neoadjuvant chemotherapy using taxinol and epirubicin in breast cancer

Expression of multiple resistance-associated protein and P-glycoprotein in oral squamous cell carcinoma for prediction of response to neoadjuvant chemotherapy

非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片

Related Author

Zhang Jieqiu

Wu Qi

Wang Jianmei

Yao Xiaopeng

陈睿

孙德平

et al

YANG Kai

Related Institution

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

重庆医科大学基础医学研究所

Department of Oral and Maxillofacial Surgery,the First Affiliated Hospital,Chongqing Medical University

⁰